- Canada Goose Holdings Inc (NYSE:GOOS) reported fourth-quarter FY23 sales growth of 31.4% year-on-year to C$293.2 million.
- DTC revenue grew 22.6% Y/Y, and wholesale revenue increased 30.4%.
- Gross profit rose 23.5% Y/Y to C$190.3 million with a profit margin of 64.9%.
- The operating income for the quarter was C$17.2 million versus C$0.9 million. The operating margin expanded 550 basis points to 5.9%.
- The company held C$286.5 million in cash and equivalents as of April 2, 2023.
- Adjusted EBIT for the quarter increased 122.6% to C$27.6 million. The adjusted EBIT margin was 9.4%.
- Non-IFRS adjusted EPS was C$0.14 versus C$0.04 last year.
- Inventory was C$472.6 million as of April 2, 2023, compared to C$393.3 million as of April 3, 2022.
- Outlook: Canada Goose sees FY24 revenue of C$1.4 billion – C$1.5 billion. Non-IFRS adjusted EPS of C$1.20 – C$1.48.
- For Q1, it sees revenue of C$70 million – C$80 million. Non-IFRS adjusted EPS of C$(0.89) – C$(0.82).
- Price Action: GOOS shares traded higher by 11.15% at $22.72 in premarket on the last check Thursday.
Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program To Evaluate Automated Manufacturing Of CAR-T Cell Therapy On The Cell Shuttle Platform
Cellares to provide proof-of-concept manufacturing for a key BMS CAR-T cell therapy
Cellares' proprietary Cell Shuttle is a cost-efficient, reliable, fully automated, and highly scalable manufacturing
